PTC Therapeutics is a global biopharmaceutical company that discovers, develops, and commercializes clinically differentiated medicines for rare disorders across neurology and metabolism, serving patients both in children and adults worldwide. The company generates revenue through net product sales from its proprietary and licensed therapeutics, collaboration and license agreements with major pharmaceutical partners, and royalties from partnered programs; it has diversified its revenue by monetizing future royalty streams through sales to specialized finance partners. PTC operates internationally across the US, Europe, and emerging markets, distributing its products through hospitals, specialty pharmacies, retail pharmacies, and wholesale distributors, while maintaining a pipeline of clinical and preclinical candidates aimed at addressing unmet needs in rare genetic and metabolic diseases.